GLP1R and type 2 diabetes mellitus: Given that GLP-1 is a potent inhibitor of glucagon in patients with type 2 diabetes [109], it not surprising that glucagon concentrations seem to diminish following dual incretin receptor agonist treatment—although this observation is far from consistent and supported by only two studies [126,129].